<DOC>
	<DOCNO>NCT00327652</DOCNO>
	<brief_summary>This clinical trial evaluate safety tolerability CRS-100 , investigational agent contain live-attenuated strain Listeria monocytogenes ( Lm ) . CRS-100 attenuate genetic modification limit cell cell spread invasion liver cell . These attenuation result decreased virulence CRS-100 mouse retain ability investigational agent stimulate immunity test animal generate anti-tumor activity mouse . The primary objective study determine maximum tolerate dose ( MTD ) explore safety profile single intravenous dose CRS-100 consenting volunteer . Immunological response CRS-100 tumor status study participant also measure . Participation first clinical trial CRS-100 restrict adult carcinoma refractory standard treatment ( standard treatment available ) additionally liver metastasis .</brief_summary>
	<brief_title>Study Safety Tolerability Intravenous CRS-100 Adults With Carcinoma Liver Metastases</brief_title>
	<detailed_description>Patients consent participate study evaluate eligibility accord medical history , physical examination , blood testing , compute tomography ( CT ) scan thorax , abdomen , pelvis . Those patient qualify study receive single intravenous dose CRS-100 study day 1 , remain hospital five day safety monitor health status , include serial blood collection . Study participant return out-patient follow-up blood test additional monitoring safety immune response CRS-100 . At day 56 , administration CRS-100 , participant repeat CT scan measure tumor size , discharge study .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Neoplasms , Second Primary</mesh_term>
	<mesh_term>Liver Neoplasms</mesh_term>
	<criteria>Inclusion Criteria ( abbreviate ) : 1 . Documented carcinoma refractory standard treatment ( standard treatment available ) . Hepatocellular carcinoma ( HCC ) allow . 2 . Hepatic metastasis 3 . ECOG Performance Status 0 1 , Karnofsky Performance Status ( KPS ) 80 % 100 % . 4 . Adequate organ function define clinical hematology chemistry assay . Exclusion Criteria ( abbreviate ) : 1 . Known central nervous system metastasis . 2 . History allergic reaction attribute sulfa betalactam antibiotic . 3 . Cardiac condition associate high moderaterisk endocarditis . 4 . Intraarterial hepatic catheter , hepatic cirrhosis , clinically relevant ascites . 5 . Artificial ( prosthetic ) joint artificial implant device easily remove . 6 . Known coagulation disorder recent thromboembolic event . 7 . Use immunosuppressive agent , chemotherapy , radiation therapy within 28 day prior CRS100 ; bone marrow stem cell transplant major organ allograft ; autoimmune disease . 8 . Current history gallstone kidney stone . 9 . Infection HIV , human tlymphotropic virus type 1 ( HTLV1 ) , hepatitis c virus ( HCV ) , hepatitis b virus ( HBV ) . 10 . Pregnant lactating</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2008</verification_date>
	<keyword>carcinoma</keyword>
	<keyword>liver</keyword>
	<keyword>hepatic</keyword>
	<keyword>metastasis</keyword>
	<keyword>Listeria</keyword>
</DOC>